Asters Advises Aspen on Ukrainian Merger Control Matters Related to Acquisition of GSK's Anesthesia Portfolio

Asters Advises Aspen on Ukrainian Merger Control Matters Related to Acquisition of GSK's Anesthesia Portfolio

Ukraine
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Asters has advised Aspen Pharmacare Holdings Limited on its successful application for merger clearance from the Ukrainian competition authority for the purchase of GlaxoSmithKline plc's anesthesia portfolio for approximately GBP 180 million plus milestones of up to GBP 100 million.

Aspen Pharmacare Holdings Limited is a global supplier and manufacturer of branded and generic pharmaceutical products as well as "infant nutritionals" and consumer healthcare products. The company has 26 manufacturing facilities at 18 sites across 6 continents and has more than 10,000 employees.

GlaxoSmithKline plc is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company as of 2015.

The Asters team included Partner Igor Svechkar, Counsel Tetiana Vovk, and Associate Pavlo Verbolyuk.